Clopidogrel News and Research

RSS
Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
Clopidogrel monotherapy linked with reduced risk of net adverse clinical events, study finds

Clopidogrel monotherapy linked with reduced risk of net adverse clinical events, study finds

Scientists identify innovative treatment approach for arterial thromboses

Scientists identify innovative treatment approach for arterial thromboses

Patients treated with edoxaban after TAVR do not find reduction in mini strokes, blood clots in the brain

Patients treated with edoxaban after TAVR do not find reduction in mini strokes, blood clots in the brain

AAN issues practice advisory for preventing second stroke in people with intracranial atherosclerosis

AAN issues practice advisory for preventing second stroke in people with intracranial atherosclerosis

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients

Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients

Trial examines differences in gastrointestinal effects of antiplatelet therapy after PCI

Trial examines differences in gastrointestinal effects of antiplatelet therapy after PCI

Research reveals a new role for platelets in COVID-19 blood vessel damage

Research reveals a new role for platelets in COVID-19 blood vessel damage

Trial tests effectiveness of two prospective stroke therapies over standard of care

Trial tests effectiveness of two prospective stroke therapies over standard of care

ESO guidelines focus on early management of transient ischemic attack

ESO guidelines focus on early management of transient ischemic attack

Study highlights the role of genetic testing in evaluation of in-stent thrombosis

Study highlights the role of genetic testing in evaluation of in-stent thrombosis

Potent antiplatelet drug not superior to standard of care in reducing heart attack risk during angioplasty

Potent antiplatelet drug not superior to standard of care in reducing heart attack risk during angioplasty

Study shows best antiplatelet treatment after transcatheter aortic valve implantation

Study shows best antiplatelet treatment after transcatheter aortic valve implantation

Personalized genetic testing helps reduce adverse events following balloon angioplasty

Personalized genetic testing helps reduce adverse events following balloon angioplasty

Precision medicine can determine the best drug treatment for severe heart disease

Precision medicine can determine the best drug treatment for severe heart disease

Study provides indications and techniques of lower extremity revascularization

Study provides indications and techniques of lower extremity revascularization

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

Clinical trial using genetic testing to guide antiplatelet therapy post-PCI falls short of stated goal

Clinical trial using genetic testing to guide antiplatelet therapy post-PCI falls short of stated goal

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

Adding antiplatelet therapy to oral anticoagulants raises risk for TAVR patients with atrial fibrillation

Adding antiplatelet therapy to oral anticoagulants raises risk for TAVR patients with atrial fibrillation